Is Spotify a Millionaire-Maker Stock?
Spotify (NYSE:SPOT) may seem like an expensive proposition trading closer…
Buy
55
MDT Quote, Financials, Valuation and Earnings
Last price:
$83.49
Seasonality move
:
3.07%
Day range:
$83.16 - $84.58
52-week range:
$75.96 - $96.25
Dividend yield:
3.35%
P/E ratio:
25.42x
P/S ratio:
3.27x
P/B ratio:
2.17x
Volume:
6.1M
Avg. volume:
7.2M
1-year change:
2.54%
Market cap:
$107.2B
Revenue:
$32.4B
EPS (TTM):
$3.29
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MDT
Medtronic PLC
|
$8.8B | $1.58 | 2.59% | 221.68% | $97.10 |
|
ABT
Abbott Laboratories
|
$10.4B | $1.07 | 6.07% | 68.64% | $140.22 |
|
BSX
Boston Scientific
|
$4.6B | $0.67 | 18.78% | 229.2% | $116.12 |
|
PODD
Insulet
|
$543.3M | $0.79 | 18.28% | -65.84% | $319.01 |
|
RMD
ResMed
|
$1.3B | $2.36 | 8.17% | 24.05% | $264.49 |
|
SYK
Stryker
|
$5.7B | $2.73 | 9.23% | 43.24% | $423.98 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MDT
Medtronic PLC
|
$83.62 | $97.10 | $107.2B | 25.42x | $0.70 | 3.35% | 3.27x |
|
ABT
Abbott Laboratories
|
$134.00 | $140.22 | $233.1B | 17.38x | $0.59 | 1.7% | 5.53x |
|
BSX
Boston Scientific
|
$103.29 | $116.12 | $152.8B | 75.39x | $0.00 | 0% | 8.76x |
|
PODD
Insulet
|
$257.00 | $319.01 | $18.1B | 44.39x | $0.00 | 0% | 9.17x |
|
RMD
ResMed
|
$243.09 | $264.49 | $35.6B | 27.28x | $0.53 | 0.87% | 7.14x |
|
SYK
Stryker
|
$382.46 | $423.98 | $146.2B | 51.68x | $0.84 | 0.86% | 6.36x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MDT
Medtronic PLC
|
34.97% | 0.573 | 22.74% | 1.19x |
|
ABT
Abbott Laboratories
|
21.34% | 0.621 | 6.18% | 1.27x |
|
BSX
Boston Scientific
|
33.49% | 1.029 | 7.48% | 0.68x |
|
PODD
Insulet
|
53.47% | 1.663 | 7.6% | 2.50x |
|
RMD
ResMed
|
10.82% | 0.505 | 2.05% | 1.99x |
|
SYK
Stryker
|
44.5% | 1.153 | 12.02% | 0.80x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MDT
Medtronic PLC
|
$5.5B | $1.7B | 5.58% | 8.56% | 20.73% | $2.1B |
|
ABT
Abbott Laboratories
|
$5.9B | $1.7B | 23.5% | 31.31% | 18.43% | $933M |
|
BSX
Boston Scientific
|
$3.2B | $937M | 6.35% | 9.57% | 19.02% | $277M |
|
PODD
Insulet
|
$430.9M | $109.3M | 17.64% | 43.11% | 20.08% | $91.7M |
|
RMD
ResMed
|
$766.4M | $426.3M | 22.47% | 25.76% | 33% | $554.9M |
|
SYK
Stryker
|
$3.7B | $872M | 8.33% | 14.2% | 14.87% | $127M |
Medtronic PLC vs. Competitors
-
Which has Higher Returns MDT or ABT?
Abbott Laboratories has a net margin of 15.61% compared to Medtronic PLC's net margin of 12.79%. Medtronic PLC's return on equity of 8.56% beat Abbott Laboratories's return on equity of 31.31%.
Company Gross Margin Earnings Per Share Invested Capital MDTMedtronic PLC66.49% $1.01 $76.2B ABTAbbott Laboratories56.86% $0.76 $62.3B -
What do Analysts Say About MDT or ABT?
Medtronic PLC has a consensus price target of $97.10, signalling upside risk potential of 16.12%. On the other hand Abbott Laboratories has an analysts' consensus of $140.22 which suggests that it could grow by 4.64%. Given that Medtronic PLC has higher upside potential than Abbott Laboratories, analysts believe Medtronic PLC is more attractive than Abbott Laboratories.
Company Buy Ratings Hold Ratings Sell Ratings MDTMedtronic PLC12 13 1 ABTAbbott Laboratories12 9 0 -
Is MDT or ABT More Risky?
Medtronic PLC has a beta of 0.811, which suggesting that the stock is 18.855% less volatile than S&P 500. In comparison Abbott Laboratories has a beta of 0.742, suggesting its less volatile than the S&P 500 by 25.819%.
-
Which is a Better Dividend Stock MDT or ABT?
Medtronic PLC has a quarterly dividend of $0.70 per share corresponding to a yield of 3.35%. Abbott Laboratories offers a yield of 1.7% to investors and pays a quarterly dividend of $0.59 per share. Medtronic PLC pays 99.73% of its earnings as a dividend. Abbott Laboratories pays out 28.62% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios MDT or ABT?
Medtronic PLC quarterly revenues are $8.3B, which are smaller than Abbott Laboratories quarterly revenues of $10.4B. Medtronic PLC's net income of $1.3B is lower than Abbott Laboratories's net income of $1.3B. Notably, Medtronic PLC's price-to-earnings ratio is 25.42x while Abbott Laboratories's PE ratio is 17.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medtronic PLC is 3.27x versus 5.53x for Abbott Laboratories. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MDTMedtronic PLC3.27x 25.42x $8.3B $1.3B ABTAbbott Laboratories5.53x 17.38x $10.4B $1.3B
-
Which has Higher Returns MDT or BSX?
Boston Scientific has a net margin of 15.61% compared to Medtronic PLC's net margin of 14.45%. Medtronic PLC's return on equity of 8.56% beat Boston Scientific's return on equity of 9.57%.
Company Gross Margin Earnings Per Share Invested Capital MDTMedtronic PLC66.49% $1.01 $76.2B BSXBoston Scientific68.84% $0.45 $33.6B -
What do Analysts Say About MDT or BSX?
Medtronic PLC has a consensus price target of $97.10, signalling upside risk potential of 16.12%. On the other hand Boston Scientific has an analysts' consensus of $116.12 which suggests that it could grow by 12.42%. Given that Medtronic PLC has higher upside potential than Boston Scientific, analysts believe Medtronic PLC is more attractive than Boston Scientific.
Company Buy Ratings Hold Ratings Sell Ratings MDTMedtronic PLC12 13 1 BSXBoston Scientific23 4 0 -
Is MDT or BSX More Risky?
Medtronic PLC has a beta of 0.811, which suggesting that the stock is 18.855% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.685, suggesting its less volatile than the S&P 500 by 31.536%.
-
Which is a Better Dividend Stock MDT or BSX?
Medtronic PLC has a quarterly dividend of $0.70 per share corresponding to a yield of 3.35%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medtronic PLC pays 99.73% of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend. Medtronic PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios MDT or BSX?
Medtronic PLC quarterly revenues are $8.3B, which are larger than Boston Scientific quarterly revenues of $4.7B. Medtronic PLC's net income of $1.3B is higher than Boston Scientific's net income of $674M. Notably, Medtronic PLC's price-to-earnings ratio is 25.42x while Boston Scientific's PE ratio is 75.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medtronic PLC is 3.27x versus 8.76x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MDTMedtronic PLC3.27x 25.42x $8.3B $1.3B BSXBoston Scientific8.76x 75.39x $4.7B $674M
-
Which has Higher Returns MDT or PODD?
Insulet has a net margin of 15.61% compared to Medtronic PLC's net margin of 16.85%. Medtronic PLC's return on equity of 8.56% beat Insulet's return on equity of 43.11%.
Company Gross Margin Earnings Per Share Invested Capital MDTMedtronic PLC66.49% $1.01 $76.2B PODDInsulet72.12% $1.39 $2.6B -
What do Analysts Say About MDT or PODD?
Medtronic PLC has a consensus price target of $97.10, signalling upside risk potential of 16.12%. On the other hand Insulet has an analysts' consensus of $319.01 which suggests that it could grow by 22.02%. Given that Insulet has higher upside potential than Medtronic PLC, analysts believe Insulet is more attractive than Medtronic PLC.
Company Buy Ratings Hold Ratings Sell Ratings MDTMedtronic PLC12 13 1 PODDInsulet13 5 0 -
Is MDT or PODD More Risky?
Medtronic PLC has a beta of 0.811, which suggesting that the stock is 18.855% less volatile than S&P 500. In comparison Insulet has a beta of 1.263, suggesting its more volatile than the S&P 500 by 26.336%.
-
Which is a Better Dividend Stock MDT or PODD?
Medtronic PLC has a quarterly dividend of $0.70 per share corresponding to a yield of 3.35%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medtronic PLC pays 99.73% of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend. Medtronic PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios MDT or PODD?
Medtronic PLC quarterly revenues are $8.3B, which are larger than Insulet quarterly revenues of $597.5M. Medtronic PLC's net income of $1.3B is higher than Insulet's net income of $100.7M. Notably, Medtronic PLC's price-to-earnings ratio is 25.42x while Insulet's PE ratio is 44.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medtronic PLC is 3.27x versus 9.17x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MDTMedtronic PLC3.27x 25.42x $8.3B $1.3B PODDInsulet9.17x 44.39x $597.5M $100.7M
-
Which has Higher Returns MDT or RMD?
ResMed has a net margin of 15.61% compared to Medtronic PLC's net margin of 28.26%. Medtronic PLC's return on equity of 8.56% beat ResMed's return on equity of 25.76%.
Company Gross Margin Earnings Per Share Invested Capital MDTMedtronic PLC66.49% $1.01 $76.2B RMDResMed59.33% $2.48 $6.2B -
What do Analysts Say About MDT or RMD?
Medtronic PLC has a consensus price target of $97.10, signalling upside risk potential of 16.12%. On the other hand ResMed has an analysts' consensus of $264.49 which suggests that it could grow by 8.8%. Given that Medtronic PLC has higher upside potential than ResMed, analysts believe Medtronic PLC is more attractive than ResMed.
Company Buy Ratings Hold Ratings Sell Ratings MDTMedtronic PLC12 13 1 RMDResMed8 6 1 -
Is MDT or RMD More Risky?
Medtronic PLC has a beta of 0.811, which suggesting that the stock is 18.855% less volatile than S&P 500. In comparison ResMed has a beta of 0.783, suggesting its less volatile than the S&P 500 by 21.661%.
-
Which is a Better Dividend Stock MDT or RMD?
Medtronic PLC has a quarterly dividend of $0.70 per share corresponding to a yield of 3.35%. ResMed offers a yield of 0.87% to investors and pays a quarterly dividend of $0.53 per share. Medtronic PLC pays 99.73% of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios MDT or RMD?
Medtronic PLC quarterly revenues are $8.3B, which are larger than ResMed quarterly revenues of $1.3B. Medtronic PLC's net income of $1.3B is higher than ResMed's net income of $365M. Notably, Medtronic PLC's price-to-earnings ratio is 25.42x while ResMed's PE ratio is 27.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medtronic PLC is 3.27x versus 7.14x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MDTMedtronic PLC3.27x 25.42x $8.3B $1.3B RMDResMed7.14x 27.28x $1.3B $365M
-
Which has Higher Returns MDT or SYK?
Stryker has a net margin of 15.61% compared to Medtronic PLC's net margin of 11.15%. Medtronic PLC's return on equity of 8.56% beat Stryker's return on equity of 14.2%.
Company Gross Margin Earnings Per Share Invested Capital MDTMedtronic PLC66.49% $1.01 $76.2B SYKStryker63.83% $1.69 $37.7B -
What do Analysts Say About MDT or SYK?
Medtronic PLC has a consensus price target of $97.10, signalling upside risk potential of 16.12%. On the other hand Stryker has an analysts' consensus of $423.98 which suggests that it could grow by 10.86%. Given that Medtronic PLC has higher upside potential than Stryker, analysts believe Medtronic PLC is more attractive than Stryker.
Company Buy Ratings Hold Ratings Sell Ratings MDTMedtronic PLC12 13 1 SYKStryker13 9 0 -
Is MDT or SYK More Risky?
Medtronic PLC has a beta of 0.811, which suggesting that the stock is 18.855% less volatile than S&P 500. In comparison Stryker has a beta of 0.929, suggesting its less volatile than the S&P 500 by 7.091%.
-
Which is a Better Dividend Stock MDT or SYK?
Medtronic PLC has a quarterly dividend of $0.70 per share corresponding to a yield of 3.35%. Stryker offers a yield of 0.86% to investors and pays a quarterly dividend of $0.84 per share. Medtronic PLC pays 99.73% of its earnings as a dividend. Stryker pays out 40.73% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios MDT or SYK?
Medtronic PLC quarterly revenues are $8.3B, which are larger than Stryker quarterly revenues of $5.9B. Medtronic PLC's net income of $1.3B is higher than Stryker's net income of $654M. Notably, Medtronic PLC's price-to-earnings ratio is 25.42x while Stryker's PE ratio is 51.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medtronic PLC is 3.27x versus 6.36x for Stryker. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MDTMedtronic PLC3.27x 25.42x $8.3B $1.3B SYKStryker6.36x 51.68x $5.9B $654M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Is a Millionaire-Maker Stock?
From time to time, investors will run across the term…
5 Investors to Follow Other Than Warren Buffett
There is no doubt that Warren Buffett is one of…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Buy
63
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Buy
99
DAVE alert for May 9
Dave [DAVE] is up 9.31% over the past day.
Buy
52
QDEL alert for May 9
QuidelOrtho [QDEL] is down 0.22% over the past day.
Buy
61
TPC alert for May 9
Tutor Perini [TPC] is up 9.61% over the past day.
